Literature DB >> 28967293

Psychometric properties of the French version of the Rating Scale of Attentional Behaviour.

Claire Vallat-Azouvi1,2,3, Clémence Dana-Gordon4, Jean-Michel Mazaux4, Jennie Ponsford5, Philippe Azouvi3,6.   

Abstract

The Rating Scale of Attentional Behaviour (RSAB) was devised by Ponsford and Kinsella to assess the impact of attentional impairments on everyday behaviour. The scale includes 14 items. The objective of this study was to assess the psychometric properties of a French translation of the RSAB. A sample of 196 healthy participants and 27 patients with chronic acquired brain injury was included. For healthy participants, both self and a relative's ratings were independently recorded. For the patients, a therapist's rating was obtained in addition. The scale showed good internal consistency. A mild significant effect of education duration was found in the healthy control group. Principal component analysis in healthy participants (self-assessment) yielded three underlying factors accounting for 58.2% of the variance. The scale was able to adequately discriminate patients from healthy controls. The area under the ROC curve was 0.76 both for self- and proxy ratings. In the patient group, the item related to fatigue was the one that obtained the highest ranking. RSAB ratings were poorly related to neuropsychological testing, but proxy ratings were significantly correlated with other questionnaires assessing cognitive failures, mood and fatigue.

Entities:  

Keywords:  Attention; rehabilitation; stroke; traumatic brain injury

Mesh:

Year:  2017        PMID: 28967293     DOI: 10.1080/09602011.2017.1372296

Source DB:  PubMed          Journal:  Neuropsychol Rehabil        ISSN: 0960-2011            Impact factor:   2.868


  1 in total

1.  Comparison of attention process training and activity-based attention training after acquired brain injury: A randomized controlled study.

Authors:  Kristina Sargénius Landahl; Marie-Louise Schult; Kristian Borg; Aniko Bartfai
Journal:  J Rehabil Med       Date:  2021-10-28       Impact factor: 2.912

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.